Akèy › Limfom selil mantèl
Etid klinik pou Limfom selil mantèl ap rekrite nan Etazini
69 etid pou Limfom selil mantèl ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Baldwin Park, CA15 etid
- Houston, TX15 etid
- Durham, NC13 etid
- Seattle, WA13 etid
- New York City, NY12 etid
- Milwaukee, WI12 etid
- Columbus, OH11 etid
- Boston, MA11 etid
- Nashville, TN10 etid
- Chicago, IL10 etid
- Portland, OR9 etid
- Rochester, MN9 etid
- Atlanta, GA8 etid
- St. Louis, MO8 etid
- Denver, CO8 etid
- Cleveland, OH7 etid
- Los Angeles, CA7 etid
- Mountain View, CA7 etid
- Jacksonville, FL6 etid
- Salt Lake City, UT6 etid
- Ann Arbor, MI6 etid
- Miami, FL6 etid
- Dallas, TX6 etid
- Baltimore, MD5 etid
- Charlotte, NC5 etid
- Philadelphia, PA5 etid
- Edison, NJ5 etid
- Kansas City, MO5 etid
- San Diego, CA5 etid
- New Haven, CT5 etid
- Tampa, FL5 etid
- Washington, DC5 etid
- Buffalo, NY5 etid
- Charlottesville, VA4 etid
- Pittsburgh, PA4 etid
- Providence, RI4 etid
- Minneapolis, MN4 etid
- Richmond, VA4 etid
- Birmingham, AL4 etid
- Queens, NY4 etid
Pa eta
- Alabama4 etid
- Arizona6 etid
- Colorado10 etid
- Connecticut6 etid
- Delaware3 etid
- Florid16 etid
- Georgia9 etid
- Illinois10 etid
- Indiana4 etid
- Iowa5 etid
- Kalifòni29 etid
- Kansas7 etid
- Kentucky4 etid
- Lwizyàn3 etid
- Maryland9 etid
- Massachusetts13 etid
- Michigan8 etid
- Minnesota14 etid
- Missouri8 etid
- Nebraska4 etid
- New Jersey8 etid
- New York16 etid
- North Carolina17 etid
- Ohio16 etid
- Oregon9 etid
- Pennsylvania9 etid
- Rhode Island4 etid
- Tennessee11 etid
- Texas19 etid
- Utah6 etid
- Virginia7 etid
- Washington15 etid
- Wisconsin13 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06252675The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07285044A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06542250A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06697184A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06742996Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06553872Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06784167A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT06029309Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07003295Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07225439A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06564038Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT05976763A Study of ARC-02 in B-cell NHL
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07691606Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT07673367AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06340737Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Ap rekriteFaz 1
Laj 18 a 85 · Tout sèks · Mizajou Aug 10, 2026 · NCT05887167Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Aug 7, 2026 · NCT05724121LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Ap rekriteFaz 1
Laj 18 a 81 · Tout sèks · Mizajou Aug 6, 2026 · NCT05990465Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06675123A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT07121946DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.